Venezuela Medical Device Risk Classification: Class I to IV in Practice

1. Key takeaways

Venezuela applies risk-based classification to medical devices, but industry material circulates two parallel classification schemes: one with classes I to IV (four levels) and another with classes I to III (three levels). The difference has not been officially reconciled in publicly available sources and sits at the level of a practical estimate.

The correct practical approach is therefore not to determine the class first, but to confirm the classification scheme currently applied by the intake window and then determine the class within that scheme. Reversing the order produces a mismatch between the document list and the class level, and the mismatch is discovered only when the file is reviewed.

The reason the mismatch is costly is that the two schemes do not merely differ by one band. A product that falls in class III under a three-level scheme may fall in class III or in class IV under a four-level scheme, and the dossier expectations attached to the top band are heavier than those attached to the third band of three. Classification is thus a decision about workload and evidence, taken before any of that work begins.

2. Legal basis

Statement on sourcing: the two classification schemes described in this article, classes I to IV and classes I to III, together with the figures of 5 years of validity and an official review period of 20 working days, were not supported during this verification by a Venezuelan official instrument that can be cited directly. They are marked as a practical estimate. The scheme in force must be confirmed with the intake window before a project is executed.

3. Expert insights

Insight 1: risk classification and tariff classification are two parallel identification systems in Venezuela. The first determines the depth of the dossier, including clinical data and biocompatibility, while the second determines the customs requirements, in other words which legal regime applies. Companies frequently attend to only one of them. This is why Article 07 emphasizes classification first: the tariff code is a legal requirement, whereas the risk class mainly affects the volume of documentation.

Insight 2: some sources indicate that Venezuelan classification rests closer to intended use than to risk. If that reading is correct, the same product may be classified differently in Venezuela than it is at ANVISA in Brazil or at ANMAT in Argentina, and conclusions reached for other Latin American markets cannot simply be transplanted. For companies filing in several countries at once, the effect is significant, because a single global class assumption becomes a source of divergent filings.

Insight 3: the practical value of the class lies in the document list and the expected duration, not in the difficulty of approval. The main difference for higher-class products is the requirement for clinical evidence and traceability, as examined in Article 18, rather than a stricter review standard. Reading the class as a scale of difficulty misdirects where resources are placed: effort goes into anticipating objections instead of into producing the evidence that the class actually requires.

Taken together, the three insights suggest a simple discipline. Confirm the scheme, record the basis, cross-check against the tariff code, and keep the class description consistent across the technical file, the label and the instructions for use. Each of these steps is cheap at the start and expensive to reconstruct later, and none of them requires waiting for an official clarification that may never arrive.

It is worth adding that the absence of a binding public classification catalogue is not the same as the absence of a rule. A reviewer applies a scheme, and that scheme produces a result. The task for the applicant is to establish which scheme is being applied at the time of filing and to document that determination, so that the resulting class is a recorded decision with a stated basis rather than an assumption inherited from another market.

4. Practical recommendations

1. Begin the classification exercise by confirming in writing which scheme the intake window currently applies, four-level or three-level, and file the confirmation in the project record.
2. Do not carry over classification conclusions from Brazil, Argentina or other Latin American markets. Where a comparison is genuinely useful, state the differences explicitly and justify the Venezuelan conclusion on its own terms.
3. Keep the classification conclusion consistent with the wording used in the technical file, the label and the instructions for use, because inconsistency becomes a ground for a deficiency notice.
4. If the product sits on the boundary between two classes, prepare the documentation for the higher class. The cost of submitting additional material on a lower classification is lower than the cost of upgrading after submission.

5. Verification checklist

• □ Confirmed in writing which classification scheme the intake window currently applies (I to IV, or I to III)
• □ Marked the classification conclusion in the internal ledger as a practical estimate, with the source and date of confirmation
• □ Cross-checked the classification conclusion against the tariff classification, with no conflict remaining
• □ Aligned the description of the product class across the technical file, label and instructions for use
• □ Compiled the document list corresponding to the class, preparing boundary cases at the higher class

Regulatory information verified as of October 29, 2026.

For a Venezuela market-entry feasibility assessment covering your specific product, contact the GRZAN regulatory team. GRZAN supports manufacturers, importers and authorized representatives with device registration in Venezuela: confirming the scheme applied by the intake window, documenting classification conclusions as practical estimates, and building dossier lists matched to the class actually in force. Reach us at info@grzanglobal.com.